{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T05:06:30Z","timestamp":1769922390788,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11596-022-2573-9","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T12:30:55Z","timestamp":1650630655000},"page":"513-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice"],"prefix":"10.1007","volume":"42","author":[{"given":"Shu-tong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"issue":"10","key":"2573_CR1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s12325-009-0072-z","volume":"26","author":"LL Stein","year":"2009","unstructured":"Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther, 2009,26(10):893\u2013907","journal-title":"Adv Ther"},{"issue":"4","key":"2573_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.bpg.2014.07.008","volume":"28","author":"P Dietrich","year":"2014","unstructured":"Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol, 2014,28(4):637\u2013653","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"2573_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/jgh.12106","volume":"28","author":"MM Smits","year":"2013","unstructured":"Smits MM, Ioannou GN, Boyko EJ, et al. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol, 2013,28(4):664\u2013670","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"2573_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/hep.26663","volume":"59","author":"N Santoro","year":"2014","unstructured":"Santoro N, Caprio S. Nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis in obese adolescents: a looming marker of cardiac dysfunction. Hepatology, 2014,59(2):372\u2013374","journal-title":"Hepatology"},{"issue":"6","key":"2573_CR5","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/hep.26461","volume":"58","author":"B Staels","year":"2013","unstructured":"Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Hepatology, 2013,58(6):1941\u20131952","journal-title":"Hepatology"},{"issue":"5","key":"2573_CR6","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1210\/jc.2003-031907","volume":"89","author":"B Ahr\u00e9n","year":"2004","unstructured":"Ahr\u00e9n B, Landin-Olsson M, Jansson P-A, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab, 2004,89(5):2078\u20132084","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2573_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1665-2681(19)31905-2","volume":"6","author":"YH Balaban","year":"2007","unstructured":"Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol, 2007,6(4):242\u2013250","journal-title":"Ann Hepatol"},{"issue":"2","key":"2573_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1042\/CS20100372","volume":"120","author":"B Maiztegui","year":"2011","unstructured":"Maiztegui B, Borelli MI, Madrid VG, et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased \u03b2-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond), 2011,120(2):73\u201380","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"2573_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1620\/tjem.226.161","volume":"226","author":"M Ohara","year":"2012","unstructured":"Ohara M, Maesawa C, Takebe N, et al. Different susceptibility to insulin resistance and fatty liver depending on the combination of TNF-\u03b1 C-857T and adiponectin G+276T gene polymorphisms in Japanese subjects with type 2 diabetes. Tohoku J Exp Med, 2012,226(2):161\u2013169","journal-title":"Tohoku J Exp Med"},{"issue":"6","key":"2573_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005,41(6): 1313\u20131321","journal-title":"Hepatology"},{"issue":"5","key":"2573_CR11","first-page":"369","volume":"103","author":"E Senate\u015f","year":"2012","unstructured":"Senate\u015f, E, Colak Y, Ye\u015fil A, et al. Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and nonalcoholic steatohepatitis scores. Minerva Med, 2012,103(5):369\u2013376","journal-title":"Minerva Med"},{"issue":"11","key":"2573_CR12","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.bbadis.2014.08.004","volume":"1842","author":"N Gruben","year":"2014","unstructured":"Gruben N, Shiri-Sverdlov R, Koonen DPY, et al. Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison? Biochim Biophys Acta, 2014,1842(11):2329\u20132343","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"2573_CR13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1515\/hmbci-2013-0019","volume":"15","author":"AL Olson","year":"2013","unstructured":"Olson AL. Insulin resistance: cross-talk between adipose tissue and skeletal muscle, through free fatty acids, liver X receptor, and peroxisome proliferator-activated receptor-\u03b1 signaling. Horm Mol Biol Clin Investig, 2013,15(3):115\u2013121","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"1","key":"2573_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cld.2017.08.007","volume":"22","author":"V Manne","year":"2018","unstructured":"Manne V, Handa P, Kowdley KV. Pathophysiology of Nonalcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis. Clin Liver Dis, 2018,22(1):23\u201337","journal-title":"Clin Liver Dis"},{"issue":"SupplD","key":"2573_CR15","first-page":"1","volume":"47","author":"X Rabasseda","year":"2011","unstructured":"Rabasseda X. Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011). Drugs of today (Barcelona, Spain: 1998), 2011,47 Suppl D:1\u20138","journal-title":"Drugs of today (Barcelona, Spain: 1998)"},{"issue":"6","key":"2573_CR16","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2337\/db05-1602","volume":"55","author":"J Mu","year":"2006","unstructured":"Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes, 2006,55(6):1695\u20131704","journal-title":"Diabetes"},{"issue":"6","key":"2573_CR17","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/hep.30320","volume":"69","author":"J Yan","year":"2019","unstructured":"Yan J, Yao B, Kuang H, et al. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology, 2019,69(6):2414\u20132426","journal-title":"Hepatology"},{"issue":"4","key":"2573_CR18","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db10-1338","volume":"60","author":"J Shirakawa","year":"2011","unstructured":"Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes, 2011,60(4):1246\u20131257","journal-title":"Diabetes"},{"issue":"2","key":"2573_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1159\/000341510","volume":"6","author":"M Itou","year":"2012","unstructured":"Itou M, Kawaguchi T, Taniguchi E, et al. Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report. Case Rep Gastroenterol, 2012,6(2):538\u2013544","journal-title":"Case Rep Gastroenterol"},{"issue":"112","key":"2573_CR20","first-page":"2103","volume":"58","author":"T Iwasaki","year":"2011","unstructured":"Iwasaki T, Yoneda M, Inamori M, et al. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. Hepato-Gastroenterology, 2011,58(112):2103\u20132105","journal-title":"Hepato-Gastroenterology"},{"issue":"10","key":"2573_CR21","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.2337\/dc12-0199","volume":"35","author":"MR Rizzo","year":"2012","unstructured":"Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care, 2012,35(10):2076\u20132082","journal-title":"Diabetes Care"},{"key":"2573_CR22","doi-asserted-by":"crossref","unstructured":"Allam MM, Ibrahim RM, El Gazzar WB, et al. Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1\/TLR4\/NF-\u03baB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease. Arch Physiol Biochem, 2021:1\u20139","DOI":"10.1080\/13813455.2021.1975758"},{"issue":"6","key":"2573_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/dom.12060","volume":"15","author":"EJ Rhee","year":"2013","unstructured":"Rhee EJ, Lee WY, Min KW, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Obes Metab, 2013,15(6):523\u2013530","journal-title":"Diabetes Obes Metab"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-022-2573-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-022-2573-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-022-2573-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T11:33:38Z","timestamp":1700480018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-022-2573-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2573"],"URL":"https:\/\/doi.org\/10.1007\/s11596-022-2573-9","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}